Disrupting pharmacies is just the start for Hims & Hers. One of the major opportunities in healthcare today is disrupting the status quo in pharmaceuticals. Hims & Hers (HIMS -3.64%) has brought a new model to the market and is growing extremely rapidly while becoming a go-to platform for millions of users. *Stock prices used were end-of-day prices of Oct. 28, 2024. The video was published on Oct. 30, 2024. ...

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $21.52, with a +0.65% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.22%. Meanwhile, the Dow experienced a drop of 0.33%, and the technology-dominated Nasdaq saw an increase of 0.76%.Shares of the company have appreciated by 23.87% over the course of the past month, outperforming the Medical sector's loss of 3.79% and the S&P 500's gain of 1.47%.The investment community will be ...

The GLP-1 drama continues at Hims & Hers.Hims & Hers (HIMS 1.85%) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NVO -0.56%) asked the FDA to not allow companies to compound GLP-1 semaglutide. This could be a direct hit to Hims & Hers business, but the impact may not be what you think, as Travis Hoium covers in this video.*Stock prices used were end-of-day prices of Oct. 23, 2024. The video was published on Oct. 23, 2024. ...

GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. Shares of Hims & Hers (HIMS -3.58%) have been all over the map over the past few months as GLP-1s have gone from tailwind to headwind for the company's growth. But the bigger picture tells us that GLP-1s don't have a big impact on earnings, and the company's platform will grow no matter what happens to any single product. Travis Hoium breaks down the company's growth in this video. *Stock prices used were end-of-day ...

文章核心观点 - Hims & Hers 公司在过去一年中股价上涨260%,这并不令人意外 [1] - 这是一家正在重塑医疗保健,使其对用户更加实惠和便利的公司 [1] - 这是一个高风险/高回报的机会,这正是分析师寻找的内容 [1] 公司概况 - Hims & Hers 是一家上市公司,股票代码为NYSE: HIMS [1] - 公司正在重塑医疗保健,使其更加实惠和便利 [1] 行业分析 - 医疗保健行业正在经历变革,Hims & Hers 公司正在引领这一变革 [1] - 这是一个高风险/高回报的机会,吸引了分析师的关注 [1]

Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage. The change would be a boon for Hims & Hers, which makes copycat weight-loss drugs, and has benefited from the limited availability of some obesity medicines. With Monday's gains, Hims & Hers shares have more than doubled in value since the start of the year. Hims & Hers Health (HIMS) shares surg ...

Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA). The FDA announced it will allow compounding pharmacies to create and sell their own version of Eli Lilly's (LLY) weight-loss drug Mounjaro. In response, HIMS is enjoying a healthy bull gap, pacing toward its highest close since July, and has now broken above the resistant $20 level. The stock sports a 230% year-over-year gain, but stil ...

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? Hims & Hers (HIMS 4.71%) stock has been on a roller coaster about the availability of GLP-1s to its customers. However, the focus on one treatment may miss the company's strategy. In this video, Travis Hoium shows why Hims & Hers will be fine with or without GLP-1s. *Stock prices used were end-of-day prices of Oct. 7, 2024. The video was published on Oct. 8, 2024. ...

Look beyond the stock price at the business when shares are volatile. When the stock market is volatile and share prices tumble, opportunities arise to search for great businesses with stocks temporarily trading at bargain levels. When this happens, investors with a multiyear buy-and-hold strategy can shrewdly add such stocks to their portfolio while others sit on the sidelines. It's true that just because a stock is trading lower doesn't necessarily mean it has become a better buy. Sometimes, stocks trade ...

Consistently investing even moderate sums can grow your portfolio with time. Bull and bear markets come and go, and along with them come short-term investment opportunities. However, investors with a long-term buy-and-hold perspective can find opportunities in any market environment. And those opportunities don't always require a lot of available cash to tap into. Even with a more modest stash of cash -- say $500 -- to invest, you can find plenty of companies to put some or all of that amount into to benefi ...